Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Biologicals
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Long-Term Antibody Persistence at 1, 3 and 5 Years After a fourth dose of GSK Biologicals' Hib-MenCY-TT Vaccine compared to Ac-tHIB
•To evaluate the long-term antibody persistence induced by 4 doses of Hib-MenCY-TT as compared to 4 doses of ActHIB given at 2, 4, 6, and 12 to 15 months of age in terms of the percentage of subjects ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
An observational study to investigate the incidence of influenza and influenza-related complications, in adults between 50-64 years and elderly adults 65 years and over vaccinated with GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscularly
During the influenza season and during the surveillance period, in subjects >= 50 years, after vaccination with Fluarix™: To evaluate the incidence of laboratory confirmed influenza; laboratory confir...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Open Immunization Study to Determine the Reactogenicity and Immunogenicity of Fluarix/ Influsplit SSW 2005/2006 in Persons as of 18 Years of Age
1. Descriptive analysis of the humoral immune response after intramuscular administration of a trivalent influenza split vaccine 2005/2006 in persons aged over 18 years (in two parallel groups 18 – 60...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
A phase III, open, randomized, controlled, multicentre, primary & booster study to demonstrate the non-inferiority of the MenC & Hib immune responses of GSK Biologicals’ Hib-MenC vaccine co-administered with Infanrix™ penta versus NeisVac-C™ co-administered with Infanrix™ hexa when given as 2 primary doses at 3, 5 m of age & prior to a booster dose at 11 m, as well as the immunogenicity of the Hib-MenC vaccine given as a booster at 11 m & the persistence of antibodies prior to the booster dose
Primary vaccination (at 1 m post dose 2): To demonstrate the non-inferiority of the Men-C and Hib immune responses induced by GSK Biologicals’ Hib-MenC conjugate vaccine given concomitantly with Infan...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Immunogenicity and safety study of GlaxoSmithKline Biologicals' Havrix administered on a 0, 6-month schedule concomitantly with GlaxoSmithKline Biologicals' Infanrix and Aventis Pasteur's Ac-tHIB in healthy children 15 months of age
To demonstrate non-inferiority of the anti-HAV immune response (with respect to both seropositivity rates and GMCs) 31 days following the second dose of Havrix when the first dose of Havrix is co-admi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
A phase IIb, controlled, randomised, multicenter, observer blinded study to demonstrate the lot-to-lot consistency of three consecutive production lots of low dose of influenza vaccine adjuvanted with AS03, and to evaluate the safety of low dose of influenza vaccine adjuvanted with AS03 compared to Fluarix™ (GlaxoSmithKline Biologicals) administered intramuscularly in elderly 60 years and older
•To demonstrate the lot-to-lot consistency of 3 lots of the low dose adjuvanted (AS03) influenza vaccine in terms of immunogenicity, 21 days after vaccination. •To assess the safety and reactogenicity...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Immunogenicity and safety study of GlaxoSmithKline Biologicals’ Infanrix hexa vaccine in healthy infants
To assess the immune response to the Hib component of GSK Biologicals’ combined DTPa-HBV-IPV/Hib preservative-free vaccine in terms of seroprotection rates one month after the three-dose primary vacci...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Biologicals S.A
MAJ Il y a 5 ans
Revaccination of healthy non-pregnantwomen with a second dose of a vaccine to asess its safety and the protection it gives from blood poisoning caused by a bacterium
Immunogenicity Objective To evaluate the immunogenicity of a second dose of GBS Trivalent Vaccine (5 μg without adjuvant) administered approximately 4-6 years after the initial GBS vaccination, measu...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Study to evaluate immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ quadrivalent influenza vaccine GSK2282512A when administered to children 6 to 35 months of age
•To assess the immunogenicity of FLU Q-QIV based on Center for Biologics Evaluation and Research’s (CBER)’s Seroconversion Rate (SCR) criterion for each of the four strains in children 6 to 35 months ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
A phase III, randomized, open, controlled, multicenter primary vaccination study to demonstrate the non inferiority of the immunogenicity of GSK Biologicals’ meningococcal serogroup ACWY conjugate vaccine when given as one dose with Twinrix™ versus GSK Biologicals’ meningococcal serogroup ACWY conjugate vaccine alone and versus Twinrix™ alone in healthy subjects aged 11 through 17 years
To demonstrate the non-inferiority of the MenACWY-TT conjugate vaccine co-administered with Twinrix as compared to the MenACWY-TT conjugate vaccine administered alone with respect to the serum bacteri...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
12
13
14
15
16
17
18
19
20
21
Suivant